Please use this identifier to cite or link to this item:
Title: ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis.
Authors: Madrid-Paredes, Adela
Cañadas-Garre, Marisa
Sánchez-Pozo, Antonio
Expósito-Ruiz, Manuela
Calleja-Hernández, Miguel Ángel
Keywords: ABCB1;Breast;C1236T;C3435T;Cancer;Meta-analysis
metadata.dc.subject.mesh: ATP Binding Cassette Transporter, Subfamily B
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Breast Neoplasms
Polymorphism, Single Nucleotide
Issue Date: 21-Sep-2017
Abstract: The ABCB1 gene encodes the P-glycoprotein, an efflux pump for some antineoplastic agents which acts as a resistance mechanism to chemotherapy. Three SNPs (C3435T, C1236T and G2677T/A), are the most widely studied in ABCB1. The inconsistent conclusions about the association of these polymorphisms and the response to chemotherapy in breast cancer (BC) patients prompted us to conduct a meta-analysis. A total of nine (770 patients), five (566 patients) and three studies (367 patients) relating the ABCB1 C3435T, C1236T and G2677T/A polymorphisms respectively, were included. The main analysis revealed a lack of association between ABCB1 polymorphisms and response to chemotherapy in every genetic model: C3435T (dominant OR: 0.888; 95%CI: 0.558-1.413), C1236T (dominant OR: 1.968; 95%CI: 0.609-6.362) and G2677T/A (GG vs GT + GA + TT + TA + AA OR: 0.854; 95%CI: 0.418-1.744). Stratification by ethnicity, cancer type and response criteria did not change the pattern of results. The available evidence indicates that three polymorphisms within ABCB1; C3435T, C1236T and G2677T/A, cannot be considered a reliable predictor of response to chemotherapy in BC patients.
metadata.dc.identifier.doi: 10.1016/j.suronc.2017.09.004
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons